bidrite, they invested in "potential" at moments where PPHM didn't have PIIs or PIIIs.
The company was at those times 100% RISK. People invested in that risk believing it might work. That is where the market needs bag holders and hopes there are not to much real investors (because those mostly think long term and hold on on the shares and there is no money to make from retailers that keep their shares on the shelf till the end-game because they pocket the profits (or losses) themselves).
Now the company has something. Our THREE largest RISK factors (as with most drug companies) where:
- Bavi isn't save and whatever good it does it does more harm. (RISK GONE) - Bavi is a placebo and FDA will not allow that. (RISK GONE) - PPHM did have to take breadcrumb deals on its IP/Pipelines that the profits it will make are small compared to the potential invested in. (RISK GONE)
So yes, the company HAD nothing and NOW HAS something. That is exactly the reason why now the retailers must be played out of the game, because now the shares may in the coming period start to appreciating. You will notice how the market will make huge efforts to tell retailers that PPHM value is for 3 years from now. This is the shift form - Bavi doesn't work - because that can no longer be sold to the public with the results at hand.
And the BoD/management criticism isn't taken very serious. How does one sell that PPHM has a worthless BoD/management team while the company is at its best position ever in history and they just salvaged a sabotaged clinical trial in a masterly way.
So the best strategy is to say they'll be late with enrolment (because the "They'll never find the centres" that one of our friends once wrote in analogy to PPHM finding few centres in their PII trials has also been proven wrong now) and hence later with the results, that the FDA procedure will take at least 2 years, to ignore the Fast Track assignment that SUNRISE got and certainly qualify as impossible every other grant such as an Accelerated Approval.
Believe me, there are people that will fall for this and ever share picked is a share picked. It is a slow process and time is an asset in it. Most people want things NOW. So take a detail out of a Quarterly or Annual and make the Forward Looking Statement sound as a factual promise: SK said we'll partner the next year :)
Where did SK SAY that. SK said they hope to bring partnerships to fruition the coming year. That statement in itself MAY NOT be the CAUSE of ANY PRESSURE that would make our BoD/Management give in to POOR propositions just because they want to make the ONE YEAR artificial deadline. I keep saying, in this stage better NO PARTNERSHIP then a BAD PARTNERSHIP.
Are we up against an unknown entity that you can prove exist?
Yes, like any company such as PPHM, not particularly AIMED at PPHM. The group is called Wall Street and I don't think I need to prove its existence, do I.
Just look at the sudden PPHM peaks to 3$ and drops to 1.18$, unexplained option amounts (sometimes even intra day), sudden increase of 5 Milj short interest in MAR 2014 (that was from 10 milj to 15 Milj in ONE SINGLE SHOT!), etc.
That is NOT the expected PPS behaviour of a company's stock, PPHM, that is in its BEST POSITION EVER with SUNRISE PIII 153 centres open, 60Milj$ on the Bank, no creditors, Avid brings revenue and extends, 100% ownership of pipelines and IP, etc.
So YES definitely the stock is played. certainly if we add the Breast, Liver results, the pre-clinical for CTLA-4 and PD-1, the rising interest in Bavituximab all over, NOT JUST SK telling us about the 24+ collaborations they have going, but also through biophar's reports the prove that this interst in Bavituximab is REAL (large increase in followers the last 6-12 months for Bavituximab, PPHM/Avid, Brekken, etc) the increase in papers and more and more peer-reviewed material coming, one of the KOL explicitly stating that is is not just on the KOLs list but actively participates, the more and more mentioning of phophatidylserine in presentations, papers and scientific research as related to MANY problems, etc.
And your Cotara question is MOMENTUM. The question has been popped many times, the answer given many times. last time COTARA got PIII approved it had been buried for death before too. Yet that was completely wrong.
The company has clearly stated they will focus on SUNRISE and they do COTARA PIII for Brain Cancer with a partner. And at least ONE BoD member has made a statement about Cotara at the ASM which was in-line with what I expected : They are interested to see Cotara+Bavituximab cocktails.
So it is not because they put this on a low fire, giving all priority to SUNRISE, that it is nowhere. Today PPHM must prioritise and that is what they do. If they have 5Bilj$ then they can run whatever they want at the same time. Not now.
And by the way, if they would put cash in Cotara PIII at this moment, thereby putting at risk the possible financing of SUNRISE, I think that THEN all comments about an incapable BoD would maybe be justified. However, they don't, they let it rest for now.
Market Data 
Markets 
AI
